# Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorder

> **NIH NIH R01** · MEDICAL COLLEGE OF WISCONSIN · 2024 · $509,279

## Abstract

PROJECT SUMMARY
Stimulant use disorders and overdose deaths resulting from methamphetamine use are on the rise.
Psychedelics, such as psilocybin, show therapeutic potential and efficacy against anxiety, depression,
alcoholism, and nicotine dependence, after administration of a single dose, but serotonergic psychedelics
exhibit polypharmacology and are not selective for the serotonin 5-HT2A receptor, which is necessary for
psychoactive effects. In this proposal we aim to investigate the role of 5-HT2A receptor signaling in
methamphetamine (METH) self-administration, neuroplasticity in vitro and in vivo, and on METH-induced
amotivation. These innovative studies utilize several novel and recently identified 5-HT2A selective tool
compounds with a range of G protein and β-arrestin recruitment efficacies designed to address the signaling
mechanisms involved in each of the following aims. In aim 1, we will determine the role of 5-HT2 receptors and
signaling pathways that lead to the suppression of reinforcing effects in a METH self-administration model. In
aim 2, we will examine the role of neuroplasticity in the attenuation of METH effects induced by psychedelics
and 5-HT2A selective agonists. In aim 3, we will determine the contribution of 5-HT2A and 5-HT2C receptors
toward attenuation of METH-induced amotivation using progressive ratio breakpoint task (PRBT) and
probabilistic reversal learning task (PRLT). Together, these studies will identify serotonin receptor signaling
profiles as a clear mechanism for psychedelic-induced efficacy for stimulant use disorders, with the potential to
identify neuroplastic and non-psychedelic signaling mechanisms for more effective treatments for drugs of
misuse.
1

## Key facts

- **NIH application ID:** 10987364
- **Project number:** 1R01DA061433-01
- **Recipient organization:** MEDICAL COLLEGE OF WISCONSIN
- **Principal Investigator:** ADAM L. Halberstadt
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $509,279
- **Award type:** 1
- **Project period:** 2024-05-15 → 2029-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10987364

## Citation

> US National Institutes of Health, RePORTER application 10987364, Investigations into 5-HT2A signaling mechanisms of psychedelic drugs for the treatment of stimulant use disorder (1R01DA061433-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10987364. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*